Abstract 【Objective】 To investigate the efficacy of oxaliplatin (OXA) regimen in the treatment of elderly patients with advanced primary liver cancer and its effect on serum D-dimer and CyclinD protein. 【Methods】A total of 26 patients with advanced primary liver cancer were treated in our hospital as the observation group,and 120 healthy persons in the same period as the control group. The efficacy of oxa regimen after 1,2 and 3 courses of treatment and the expression levels of D-dimer,fibrinogen,fibrinogen degradation products (FDP),CyclinD and heat shock protein 70 (HSP70) in the serum of the two groups were compared,and the adverse reactions and long-term efficacy of chemotherapy were counted. 【Results】After treatment,with the increase of the course of treatment,the proportion of complete remission and partial remission increased significantly,and there was significant difference in each course of treatment (P<0.05). Before treatment,the indexes of the observation group were significantly higher than those of the control group,and the difference was statistically significant (P<0.05). After treatment,the expression levels of D-dimer,fibrinogen,FDP,CyclinD and HSP70 in serum of patients with advanced liver cancer were significantly lower than those before treatment (P<0.05),and with the extension of treatment time,the levels of various indicators showed a gradual downward trend (P<0.05). One patient had nausea and vomiting,one had hematological toxicity and one had peripheral neurotoxicity during chemotherapy. The total adverse reaction rate was 11.54% (3/26). After 1 year follow-up,4 patients had recurrence or metastasis,and the median progression free survival was 7 months. 【Conclusion】 OXA regimen has obvious effect on elderly patients with advanced primary liver cancer,which may be related to the expression of D-dimer and CyclinD protein in serum.
LIU Huan,WANG Feng-wen,LUO Shu-ping, et al. Efficacy of OXA Regimen in the Treatment of Elderly Patients with Advanced Primary Liver Cancer and its Effect on Serum D-dimer and CyclinD Protein[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 1037-1039.
[1] 朱笑生,刘文超. 原发性肝癌全球流行情况和危险因素的新进展[J].现代肿瘤医学,2018,26(14):2297-2301.
[2] YANG J D,HAINAUT P,GORES G J,et al. A global view of hepatocellular carcinoma: trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
[3] 施婕,李瑛. 表柔比星联合奥沙利铂在原发肝癌介入治疗中的应用及对肝功能的影响[J].医学临床研究,2019,36(11):2243-2244.
[4] KANEMITSU Y,SHIMIZU Y,MIZUSAWA J,et al. Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase Ⅱ or Ⅲ randomized controlled trial[J].J Clin Oncol,2021,39(34):3789-3799.
[5] EISENHAUER E A. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[6] HARTKE J,JOHNSON M,GHABRIL M. The diagnosis and treatment of hepatocellular carcinoma[J].Semin Diagn Pathol,2017,34(2):153-159.
[7] 李达,何静. 妇科恶性肿瘤患者凝血功能及d-二聚体水平变化及意义[J].中华实用诊断与治疗杂志,2016,7(6):596-597.
[8] SAKAI M,SOHDA M,UCHIDA S,et al. Fibrin/fibrinogen degradation products are associated with tumor stage and prognosis in patients undergoing resection of esophageal cancer[J].Anticancer Res,2021,41(9):4523-4527.
[9] 张红,赵花,张琰. 恶性肿瘤患者纤维蛋白原与D-二聚体检测的临床意义[J].国际检验医学杂志,2015,14(18):2758-2759.
[10] GAO X,LEONE G W,WANG H. Cyclin D-CDK4/6 functions in cancer[J].Adv Cancer Res,2020,148(1):147-169.
[11] 赵立武,申彦,师宜荃,等. P16、p53和cyclind1蛋白在卵巢浆液性肿瘤中的表达及意义[J].解剖学研究,2012,11(4):251-255.
[12] 宋旭,周磐石,张圣熙,等. 膀胱尿路上皮癌mrp-1/cd9和cyclind1的表达与肿瘤生物学行为的关系[J].临床泌尿外科杂志,2012,17(5):389-392.
[13] 魏涛. 奥沙利铂介入治疗原发性肝癌的疗效及对患者血清CXCL9、HSP90水平的影响[J].实用癌症杂志,2021,36(5):814-819.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1257-1259.
2022, Vol. 39 
